RxDoctor Payments Data

Mark Penta, PA

Surgical · Newark, DENPI 1154456069

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by 180 Medical, Inc. at 32.3% of the total. Reporting peaked in 2021 at $111 and has fallen 81.3% since, to $21 in 2025. That places this record below the midpoint for surgical clinicians in DE, where the typical reported total is $332.

$165in general payments, 2019–2025

Across 9 payments — averaging $18.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • 180 Medical, Inc.$53
  • Gilead$22
  • Astellas Pharma US Inc$22
  • AbbVie$19
  • Takeda Pharmaceuticals U.S.A., Inc.$18
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$17
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$165100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$165 in reported general payments places this provider in the 30th percentile of 51 surgical providers in Delaware.

See all surgical providers in Delaware

Medicare billing

Part B allowed, 2024
$96,410
Medicare patients
505
Services billed
1,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron144$132,296
Tamsulosin Hcl658$13,310
Mirabegron ErMirabegron11$9,419
Finasteride336$5,926
Methenamine Hippurate48$5,734
Trospium Chloride43$4,044
Trospium Chloride ErTrospium Chloride23$3,935
Estradiol55$3,002
Solifenacin Succinate36$2,053
Oxybutynin Chloride ErOxybutynin Chloride94$1,843
Trimethoprim19$1,356
Alfuzosin Hcl ErAlfuzosin Hcl44$1,224
Testosterone25$1,175
Testosterone Cypionate11$864
Cefpodoxime Proxetil20$861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$22$132,296144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 51 surgical providers in Delaware.

Other surgical in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →